Covaxin, for the beneficiaries aged between 2-18 years, worried parents can now heave a sigh of relief. However, the final approval is yet to be given, which will be done by the Drugs Controller General of India (DCGI).
Experts said vaccination for children against Covid-19 was more necessary than ever as schools have reopened in many states.
Bharat Biotech's Covaxin for children is one of the first worldwide approval for COVID-19 vaccines for the age group of beneficiaries belonging to 2-18 years.
Bharat Biotech has submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO. The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee (SEC) and have provided their positive